Redeye returns with an update following a review of BioArctic's pipeline and latest report. We largely reiterate our positive view of the company but adjust our expectations downwards on Leqembi following Eisai's FY2028 simulation. Furthermore, following several strong deals, we raise our expectations of the Brain transporter platform.
LÄS MER
